Biotech

All Articles

A deeper take a look at Strong Biotech's Tough 15

.Within this full week's incident of "The Best Pipe," we're diving in to Fierce Biotech's yearly Fie...

Lilly faces phase 2 failure of tau-targeting med

.The confetti is still flying from Eli Lilly's party commemorating the commendation of Alzheimer's i...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, firings a...

Lykos will definitely inquire FDA to reassess its selection following denial of MDMA therapy for post-traumatic stress disorder

.Following a poor presenting for Lykos Therapies' MDMA candidate for post-traumatic stress disorder ...

AN 2 one-halfs roll call, ceases period 3 test after records let down

.AN2 Therapies is rethinking its organization in feedback to uninspired midphase records, vowing to ...

Merck pays out $700M for bispecific, spying autoimmune opening and chance to challenge Amgen in cancer

.Merck &amp Co. is actually paying out $700 million upfront to test Amgen in a blood cancer market. ...

Gilead pays for J&ampJ $320M to leave licensing offer for seladelpar

.With Gilead Sciences almost an FDA choice for its own liver health condition drug seladelpar, the c...

' All palms on deck' at Lilly as peers target being overweight market

.CEO David Ricks may view the business setting up camping tents at basecamp responsible for Eli Lill...

Entero giving up team, moving out of workplace and stopping R&ampD

.Mattress Liquidators has actually transformed Entero Therapies white colored as a sheet. The financ...

Exelixis drops ADC after choosing it's no match for Tivdak

.Exelixis is surrendering on its cells aspect (TF)- targeting antibody-drug conjugate after wrapping...